细小病毒H-1抗肿瘤作用的研究进展  

Research development of H-1 parvovirus application in cancer therapeutics

作　　者：施慧(综述)[1] 刘炯(审校)[1] 汪芳裕(审校)[1] 

机构地区：[1]南京军区南京总医院消化内科,210002

出　　处：《肿瘤研究与临床》2013年第4期281-284,共4页Cancer Research and Clinic

摘　　要：细小病毒（PV）在感染人体后没有明显症状，将其用于抗肿瘤治疗获得了较好的疗效。H-1PV对于多形性胶质母细胞瘤（GBM）、伯基特淋巴瘤、肝癌、胰腺导管腺癌（PDAC）、乳腺癌、结肠癌都有治疗效果，其抗肿瘤作用主要通过直接溶瘤活性、NS1蛋白和免疫调节实现。Since there is no specific symptoms after human have been infected by parvovirus, parvovirus was administered as a potential cancer therapeutics. Parvovirus was employed as an effective treatment in glioblastoma muhiforme, Burkitt＂ s lymphoma, liver cancer, pancreatic carcinoma, breast cancer and colon cancer. Anti-tumor effects of parvovirus were approved to be associated with its oncolytic effects, non-structural protein 1 and immunoregulation.

关 键 词：H-1细小病毒 胶质母细胞瘤 伯基特淋巴瘤 肝肿瘤 胰腺导管腺癌 病毒非结构蛋白质1 

分 类 号：R735.2[医药卫生—肿瘤]